% | $
Quotes you view appear here for quick access.

Nymox Pharmaceutical Corporation Message Board

  • ckbenergy ckbenergy Mar 26, 2007 9:08 AM Flag

    P value - ALXA

    The Phase IIa clinical trial was designed as a multi-center, randomized, double-blind, placebo-controlled study of 120 patients in an in-patient clinical setting. In the trial, two doses of AZ-004 (Staccato loxapine in 5 and 10 mg doses) and placebo (Staccato device containing no drug) were tested. The primary aim of the clinical trial was to assess the safety and efficacy of a single dose of AZ-004 in acutely treating agitation in schizophrenic patients. Assessments of a patient's agitation state were conducted at serial time points using both standard agitation scales and objective measures of patient's movement over a 4-hour period, with follow-up assessments for the next 20 hours. The change in the PANSS (Positive and Negative Symptom Scale) Excited Component (PEC) score at the 2-hour post-dose time point was the primary efficacy measure for the clinical study. All results were considered statistically significant at the p < 0.05 level and all analyses were made on an intent-to-treat basis. Side effects were recorded throughout the clinical trial study period.

    ALXA just hit 15 this morning atfer a successful phase 2.

    The shorts could wake up any morning and see double digits.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
2.33-0.02(-0.85%)3:21 PMEDT